In the aftermath of announcing a major collaboration with Sandoz on biosimilars, Evotec’s chief business officer Matthias Evers speaks about how the deal provides “validation” of Just-Evotec’s technology platform, while also outlining the firm’s wider ambitions to enable more efficient development of and broader access to biologics.
In a major deal for the off-patent industry, Sandoz recently announced a multi-year collaboration with Evotec subsidiary Just-Evotec Biologics that will see the firms develop and manufacture multiple biosimilars together.
The alliance – which Sandoz’s biosimilars head saidwould be “a game-changer” for the firm’s biopharma business (Also see "Slovenia...
BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility.
Exec summary XXXXXXX
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
